Doxycycline hyclate
Doxycycline hyclate, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hyclate can be used to construct gene expression regulation models[1][2][3][4][5].
Product Specifications
CAS Number
[24390-14-5]
Product Name Alternative
Doxycycline (hydrochloride hemiethanolate hemihydrate) ; WC2031
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Bacterial; MMP; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/Doxycycline-hyclate.html
Concentration
10mM
Purity
99.19
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 125 mg/mL (ultrasonic)
Smiles
O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])[C@@H](O)[C@]3([H])[C@@H](C)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N.Cl.[0.5H2O].[0.5C2H6O]
Molecular Formula
C22H24N2O8.1/2C2H6O.ClH.1/2H2O
Molecular Weight
512.94
Precautions
H302, H315, H319, H335
References & Citations
[1]Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337 (3) :621-7.|[2]Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534 (7609) :647-51.|[3]Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19 (5) :1504.|[4]Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8 (5) :e64561.|[5]Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16 (8) :737-745.|[6]Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93 (2) :167-73.|[7]Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93 (20) :10933-8.|[8]Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17 (11) :1857-67.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Tetracycline
Citation 01
Adv Sci (Weinh) . 2022 Aug;9 (22) :e2104823.|Adv Sci (Weinh) . 2024 Dec;11 (45) :e2404756.|Biochem Biophys Res Commun. 2022 Oct 15:625:23-30.|bioRxiv. 2019 Apr.|bioRxiv. 2024 Jan 23.|bioRxiv. 2025 April 15.|bioRxiv. 2025 January 15.|bioRxiv. 2025 July 10.|bioRxiv. 2025 March 25.|bioRxiv. 2025 Sep 10.|Cancer Commun (Lond) . 2024 Feb;44 (2) :251-272.|Cancer Res Commun. 2024 Jul 1;4 (7) :1815-1833.|Cell Death Dis. 2017 Mar 23;8 (3) :e2702.|Cell Death Dis. 2021 Apr 20;12 (5) :413.|Cell Discov. 2024 Nov 5;10 (1) :112.|Cell Mol Life Sci. 2025 Jun 5;82 (1) :224.|Cell Rep. 2021 Jun 8;35 (10) :109225.|Cell Rep. 2021 Sep 21;36 (12) :109739.|Cell Stem Cell. 2024 Jan 4;31 (1) :52-70.e8.|Elife. 2021 Oct 27;10:e65759.|EMBO Rep. 2025 Oct 20.|EMBO Rep. 2025 Sep 22.|FEBS Lett. 2025 Sep 1.|Food Funct. 2021 Dec 13;12 (24) :12535-12549.|Institute of Pharmacology and Toxicology University of Zürich. 2019 Nov.|J Biol Chem. 2022 Sep;298 (9) :102374.|J Biol Chem. 2023 May;299 (5) :104621.|J Genet Genomics. 2020 Nov 20;47 (11) :705-712.|Mol Cancer. 2020 Sep 9;19 (1) :139.|Mol Cell. 2025 Apr 17;85 (8) :1589-1605.e12.|Nat Commun. 2023 Dec 20;14 (1) :8461.|Nat Commun. 2025 Jul 1;16 (1) :5425.|Neuron. 2025 Jul 29:S0896-6273 (25) 00509-4.|Nucleic Acids Res. 2024 Aug 21:gkae707.|Oncogenesis. 2025 Aug 11;14 (1) :28.|Patent. US11576860B2.|Patent. US2019/0365645A1.|Patent. US20190365645A1.|Patent. US20190366064A1.|Research Square Preprint. 2024 Dec 04.|Research Square Print. 2022 May.|Research Square Print. 2023 Mar 1.|Rheumatology (Oxford) . 2025 Aug 13:keaf437.|STAR Protoc. 2021 May 20;2 (2) :100548.|STAR Protoc. 2021 Nov 5;2 (4) :100881.|STAR Protoc. 2022 Apr 13;3 (2) :101296.|STAR Protoc. 2023 Feb 3;4 (1) :102092.|Theranostics. 2022 Jan 1;12 (3) :1187-1203.|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|Acta Pharmacol Sin. 2024 Nov;45 (11) :2420-2431.|Adv Sci (Weinh) . 2021 Mar 15;8 (10) :2004344.|Adv Sci (Weinh) . 2025 Jan 21:e2407942.|Adv Sci (Weinh) . 2025 Jun 17:e03865.|Adv Sci (Weinh) . 2025 Oct 13:e09383.|AMB Express. 2024 Dec 24;14 (1) :141.|Ann Lab Med. 2021 May 1;41 (3) :293-301.|Biochem Biophys Res Commun. 2022 Jul 30:615:163-171.|Biochem Pharmacol. 2025 Apr 12:116948.|Biol Res. 2024 Nov 24;57 (1) :90.|Biomed Pharmacother. 2023 Aug:164:114998.|bioRxiv. 2023 Jun 14:2023.06.13.544756.|bioRxiv. 2023 Mar 31:2023.03.29.534783.|bioRxiv. 2024 July 05.|bioRxiv. 2025 August 09.|Cancer Biol Ther. 2022 Dec 31;23 (1) :328-335.|Cancer Commun (Lond) . 2025 May;45 (5) :608-631.|Cancer Res. 2023 Oct 2;83 (19) :3220-3236.|Cancer Res. 2025 Feb 1;85 (3) :585-601.|Cell Commun Signal. 2022 Apr 12;20 (1) :52.|Cell Death Differ. 2023 Jul;30 (7) :1811-1828.|Cell Death Differ. 2025 Jul 5.|Cell Death Dis. 2020 May 7;11 (5) :331.|Cell Death Dis. 2022 Feb 10;13 (2) :138.|Cell Death Dis. 2025 Mar 12;16 (1) :170.|Cell Mol Life Sci. 2024 Nov 16;81 (1) :456.|Cell Mol Life Sci. 2025 Apr 6;82 (1) :139.|Cell Prolif. 2024 Feb;57 (2) :e13534.|Cell Rep. 2024 Jul 3;43 (7) :114431.|Cell Rep. 2025 May 26;44 (6) :115748.|Cell. 2025 Jun 26;188 (13) :3405-3421.e27.|Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :604-609.|Dev Cell. 2025 Apr 18:S1534-5807 (25) 00206-0.|Diagn Microbiol Infect Dis. 2025 Nov 4;114 (2) :117181.|Drug Resist Updat. 2024 Jun 24:76:101112.|Drug Resist Updat. 2026 Jan:84:101319.|EMBO Rep. 2025 Oct 20.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|FASEB J. 2020 Dec;34 (12) :16716-16735.|FASEB J. 2024 Apr 30;38 (8) :e23628.|Front Cell Infect Microbiol. 2021 Apr 28:11:640847.|Fundam Res. 2025 Jul 8.|Heliyon. 2024 May 30.|Infect Drug Resist. 2025 Apr 23:18:2005-2020.|Infect Drug Resist. 2025 Oct 4:18:5239-5247.|Inflammopharmacology. 2025 Apr;33 (4) :1935-1947.|Int Immunopharmacol. 2024 Jun 24:138:112518.|Int J Mol Med. 2020 Apr;45 (4) :1187-1194.|Int J Mol Sci. 2025 Mar 18;26 (6) :2712.|iScience. 2023 Mar 16;26 (4) :106421.|J Cell Mol Med. 2024 Sep;28 (17) :e70053.|J Cell Mol Med. 2025 Sep;29 (17) :e70815.|J Clin Invest. 2024 Jan 18;134 (5) :e171995.|J Med Virol. 2024 May;96 (5) :e29634.|J Med Virol. 2025 May;97 (5) :e70356.|J Neuroinflammation. 2025 Oct 11;22 (1) :230.|J Transl Med. 2024 Oct 10;22 (1) :923.|J Virol. 2024 Aug 30:e0133524.|Katedra farmakologie a toxikologie. 2020 Jul.|Microbiol Spectr. 2025 May 19:e0307424.|Mol Cancer. 2020 Mar 30;19 (1) :68.|Mol Cell. 2025 Jul 17;85 (14) :2654-2672.e7.|Mol Cell. 2025 Oct 2;85 (19) :3588-3604.e11.|Mol Oncol. 2024 May 22.|Molecules. 2023 Jul 26;28 (15) :5668.|Molecules. 2025 Jul 7;30 (13) :2881.|Nat Commun. 2024 Apr 6;15 (1) :2989.|Nat Genet. 2024 Feb;56 (2) :294-305.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Nat Protoc. 2025 Oct 8.|Neurobiol Stress. 2025 Oct 28:39:100768.|NPJ Parkinsons Dis. 2022 Aug 6;8 (1) :100.|Oncogene. 2024 Dec;43 (50) :3660-3672.|Oncogene. 2024 Feb;43 (6) :434-446.|Phytomedicine. 2024 Aug 22:134:155958.|PLoS Pathog. 2025 Jul 3;21 (7) :e1013258.|Redox Biol. 2023 Jun:62:102686.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2023 Jul 11.|Research Square Preprint. 2024 Apr 8.|Research Square Preprint. 2024 Jan 23.|Sci Adv. 2022 Jan 28;8 (4) :eabl5220.|Sci Adv. 2025 Jan 31;11 (5) :eadr8837.|Sci Signal. 2025 Mar 18;18 (878) :eadi5174.|Stem Cell Res Ther. 2024 Oct 8;15 (1) :350.|Theranostics. 2022 Mar 28;12 (7) :3131-3149.|Vet Microbiol. 2024 May:292:110046.|Virol Sin. 2022 Aug;37 (4) :558-568.|Water Res. 2023 Jul 15:240:120110.|Water. 2025 Jun 6.|bioRxiv. 2025 Jun 19.|bioRxiv. 2025 May 14.|Cancer Lett. 2016 Jun 28;376 (1) :188-96.|Cell Death Differ. 2019 Nov;26 (11) :2400-2415. |Cell Rep. 2024 Aug 22;43 (9) :114662.|Cell Rep. 2025 Jul 26;44 (8) :116076.|Cell Rep. 2025 Nov 25;44 (11) :116496.|Cell. 2023 Feb 2;186 (3) :591-606.e23.|Chem Eng J. 2025 Oct 8;524:169421.|J Exp Clin Cancer Res. 2025 Mar 19;44 (1) :99.|Nat Cell Biol. 2025 Apr;27 (4) :641-653.|Neuron. 2025 Jul 23;113 (14) :2310-2324.e7.|Sci Adv. 2024 Apr 17;10 (16) :eadi1782
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6002642-01 0.2 mL
TPM2, CT (TPM2, TMSB, Tropomyosin beta chain, Beta-tropomyosin, Tropomyosin-2)
Ask
View Details 
MBS6002642-02 5x 0.2 mL
TPM2, CT (TPM2, TMSB, Tropomyosin beta chain, Beta-tropomyosin, Tropomyosin-2)
Ask
View Details 
44706111 3x 1.0 µg
SNORD114-15 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Ask
View Details MBS6130737-01 0.1 mL
CPXM2 (Inactive Carboxypeptidase-like Protein X2, UNQ676/PRO1310) (AP)
Ask
View Details MBS6130737-02 5x 0.1 mL
CPXM2 (Inactive Carboxypeptidase-like Protein X2, UNQ676/PRO1310) (AP)
Ask
View Details